NRIXNurix Therapeutics, Inc.
Price
+165%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growth fading, the market undecided.
We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully artificial intelligence (AI)-integrated discovery engine capable of tackling any protein class, and coupled with leading ligase expertise, Nurix has built a significant advantage in translating the science of protein degradation into clinical advancements with the aim of establishing degrader-based treatments at the forefront of patient care.
In the company’s own words · 10-K filed Jan 28, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Nurix Therapeutics, Inc. (NRIX) reported revenue of $9.0M in Q2 2026 (quarter ended May 31, 2026), down 79% from the same quarter a year earlier. That came with net loss of $90M. For the full year FY2025, revenue was $84M (+54% year on year) and net income −$264M. Its largest product in Q1 2026 (quarter ended Feb 28, 2026) was License at $30M, 83% of the disclosed total, well ahead of Collaboration at 17%. The next results filing is expected around Oct 8, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 9, 2026Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Jun 11, 2026On June 11, 2026, the Company announced updated data from the Phase 1 clinical trial of bexobrutideg (NX-5948)Regulation FD disclosure · Form 8-K
- Jun 8, 2026On June 6, 2026, Nurix Therapeutics, Inc. (“Nurix”) entered into a License and Collaboration Agreement (the “Collaboration Agreement”), dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, “Roche”), pursuant to which Nurix will grant Roche an exclusive worldwide license …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q1 2026 · $36.3MThe company’s own SEC segment disclosure.
- License$30.0M83%
- Collaboration$6.3M17%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.